Coy D Heldermon Selected Research

Pharmaceutical Preparations

1/2019	Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway.
4/2017	Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Coy D Heldermon Research Topics

Disease

11	Neoplasms (Cancer) 07/2022 - 11/2016
10	Breast Neoplasms (Breast Cancer) 01/2022 - 09/2014
4	Mucopolysaccharidosis III (Sanfilippo Syndrome) 01/2021 - 08/2007
3	Lysosomal Storage Diseases (Lysosomal Storage Disease) 06/2021 - 05/2010
3	Mucopolysaccharidoses 06/2021 - 08/2007
2	Febrile Neutropenia 07/2022 - 11/2021
2	Triple Negative Breast Neoplasms 01/2019 - 04/2017
2	Neoplasm Metastasis (Metastasis) 01/2019 - 01/2019
1	Lymphoma (Lymphomas) 11/2021
1	Neutropenia 11/2021
1	Pneumococcal Pneumonia 01/2020
1	Obesity 01/2020
1	Necrosis 01/2019
1	Hypoxia (Hypoxemia) 01/2018
1	Overweight 01/2018
1	Carcinoma (Carcinomatosis) 11/2016
1	Multiple Myeloma 02/2016
1	Hyponatremia 10/2014
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 10/2014
1	Neurodegenerative Diseases (Neurodegenerative Disease) 09/2014

Drug/Important Bio-Agent (IBA)

5	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2018
4	bis(p-chlorophenyl)acetic acid (DDA)IBA 01/2022 - 04/2017
4	EnzymesIBA 06/2021 - 08/2007
3	DisulfidesIBA 01/2022 - 04/2017
3	Carbonic Anhydrase IXIBA 01/2019 - 01/2018
3	Estrogen ReceptorsIBA 01/2018 - 04/2017
3	alpha-N-acetyl-D-glucosaminidase (alpha-N-acetylglucosaminidase)IBA 09/2014 - 08/2007
2	Biosimilar PharmaceuticalsIBA 07/2022 - 11/2021
2	Acetylglucosaminidase (NAGase)IBA 01/2021 - 09/2014
2	Pharmaceutical PreparationsIBA 01/2019 - 04/2017
2	CaspasesIBA 01/2019 - 01/2019
2	Lapatinib (GW572016)FDA Link 01/2019 - 01/2016
2	Cadherins (E-Cadherin)IBA 11/2016 - 09/2014
2	Hexosaminidases (Hexosaminidase)IBA 05/2010 - 08/2007
1	pegfilgrastim (Neulasta)FDA Link 07/2022
1	Death Domain ReceptorsIBA 01/2022
1	ErbB Receptors (EGF Receptor)IBA 01/2022
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 11/2021
1	GlucuronidaseIBA 06/2021
1	Oncogene Proteins (Oncogene Protein)IBA 01/2021
1	ametantrone (HAQ)IBA 01/2020
1	Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)IBA 01/2020
1	InterferonsIBA 01/2020
1	23-valent pneumococcal capsular polysaccharide vaccineIBA 01/2020
1	Attenuated VaccinesIBA 01/2020
1	Tyrosine Kinase InhibitorsIBA 01/2019
1	Carbonic Anhydrases (Carbonic Anhydrase)IBA 01/2019
1	LigandsIBA 01/2019
1	Proline (L-Proline)FDA Link 01/2019
1	Protons (Proton)IBA 01/2019
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2019
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2019
1	Peptidylprolyl Isomerase (Prolyl Isomerase)IBA 01/2019
1	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 01/2019
1	SulfonamidesIBA 01/2018
1	human ERBB2 proteinIBA 01/2018
1	Phenobarbital (Luminal)FDA Link 01/2018
1	Progesterone Receptors (Progesterone Receptor)IBA 04/2017
1	AntibodiesIBA 04/2017
1	Phosphotransferases (Kinase)IBA 04/2017
1	thymoglobulin FDA Link 02/2016
1	Hemoglobins (Hemoglobin)IBA 09/2015
1	beta-apocarotenoid-14',13'-dioxygenase (ADO)IBA 10/2014
1	Maytansine (Maitansine)IBA 10/2014
1	Epithelial Cell Adhesion MoleculeIBA 09/2014
1	Acetyl Coenzyme A (Acetyl-CoA)IBA 09/2014
1	AcetyltransferasesIBA 09/2014
1	VimentinIBA 09/2014
1	Transcription Factors (Transcription Factor)IBA 09/2014
1	heparan sulfate sulfataseIBA 09/2014
1	N-acetylglucosamine-6-sulfataseIBA 09/2014

Therapy/Procedure

4	Therapeutics 06/2021 - 04/2017
2	Drug Therapy (Chemotherapy) 07/2022 - 11/2021
1	Aftercare (After-Treatment) 01/2019
1	Hormonal Contraception 01/2018
1	Transplantation 11/2016
1	Investigational Therapies (Experimental Therapy) 09/2014